Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0YG06 | ISIN: IM00B58FMW76 | Ticker-Symbol: N/A
1-Jahres-Chart  (nicht börsennotiert)
EXILLON ENERGY PLC Chart 1 Jahr

Aktueller Chart EXILLON ENERGY Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
EXILLON ENERGY PLC-Investoren interessieren sich auch für diese Wertpapiere
RTX and Northrop Grumman conduct successful rocket motor tests for U.S. Army's Next-Generation Short-Range InterceptorRaytheon advances NGSRI development with continued testing TUCSON, Ariz., June 5, 2025 /PRNewswire/ -- Raytheon, an RTX (NYSE: RTX) business, and Northrop Grumman...
► Artikel lesen
Dividendenbekanntmachungen (02.06.2025) Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  ACCOR SA  FR0000120404 - 1,26 EUR  ASSOCIATED BANC-CORP  US0454871056  0,23 USD  0,2026 EUR  ATOUR LIFESTYLE HOLDINGS LTD ADR  US04965M1062  0...
► Artikel lesen
Northrop Grumman Invests $50Mln In Firefly's Eclipse Rocket ProgramWASHINGTON (dpa-AFX) - Northrop Grumman Corp. (NOC), Thursday announced that it has committed $50 million to Firefly Aerospace to accelerate production of their jointly developed medium class...
► Artikel lesen
Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten OfferingSangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded warrants...
► Artikel lesen
Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease All dosed patients have passed one-year milestone required by U.S. Food and Drug Administration (FDA) for Accelerated Approval regulatory pathway for ST-920. According to preliminary analysis...
► Artikel lesen
Sangamo Therapeutics, Inc.: Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) One abstract accepted as platform presentation in prestigious Presidential Symposium, demonstrating potent combination of epigenetic regulation and capsid delivery technology in treating prion...
► Artikel lesen